Jane Street
LXEO icon

Jane Street’s Lexeo Therapeutics LXEO Stock Holding History

Jane Street’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Buy
+24,900
New +$176K ﹤0.01% 10423

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's LXEO Position: Q1 2026 in Review

Jane Street sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 140,096 shares — an estimated $993K sold.

Jane Street first reported a position in LXEO in Q4 2023 and held it in 7 quarters. The position peaked at $1.39M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Jane Street reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 140,096 Lexeo Therapeutics shares in Q1 2026, an estimated $993K.
  • Jane Street first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 7 quarters.
  • Jane Street's Lexeo Therapeutics position peaked at $1.39M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.